Reading File
analyse_media
Finding Sources
Finding Sources
Reading File
Reading File
Searching PubMed
Bethesda III thyroid nodule management
Reading File
I now have everything needed for a thorough explanation. Here is a full, clear breakdown of this report:
Report Summary: Mrs. Shreya Salunkhe, 30F
Test: USG-Guided FNAC (Fine Needle Aspiration Cytology) of the Left Lobe Thyroid
Date: 16-Jul-2026 | Lab: Shraddha Pathology Laboratory, Miraj
Reporting Pathologist: Dr. Pankaj Pande, MD (Pathology)
What the Report Found
Ultrasound Findings (Clinical History)
- A single solid nodule, 13 x 12 mm in the left lobe of the thyroid - this is small (about 1.3 cm)
- Multiple punctate echogenic foci (tiny bright spots) = microcalcifications within the nodule
- Classified as TR4 (TI-RADS 4) = moderately suspicious on ultrasound
- Small bilateral lymph nodes noted (not described as significantly enlarged)
The TR4 classification and microcalcifications are important - they raise the sonographic suspicion for malignancy above baseline. This is why the FNAC was performed.
Microscopy (What the Pathologist Saw Under the Microscope)
- Four hypocellular smears - meaning the sample had relatively few cells (this is common in follicular-type lesions)
- Scattered clusters of follicular cells with focal nucleomegaly (some cells had larger nuclei than normal - a mild abnormality)
- Scanty colloid (little of the normal thyroid gel-like substance)
- Hemorrhagic background (some blood in the sample - expected with FNAC)
These features are not overtly malignant, but they are also not clearly benign.
Impression / Diagnosis
"Follicular Lesion of Undetermined Significance (FLUS)" - Bethesda Category III
This is one of 6 categories in the Bethesda System for Reporting Thyroid Cytopathology, the international standard classification:
| Bethesda Category | Meaning | Malignancy Risk | Typical Management |
|---|---|---|---|
| I | Non-diagnostic | 1-4% | Repeat FNAC |
| II | Benign | 0-3% | Observation |
| III | AUS/FLUS (this report) | 5-15% | Repeat FNAC / Molecular testing / Surgery |
| IV | Follicular Neoplasm | 15-30% | Lobectomy |
| V | Suspicious for Malignancy | 60-75% | Surgery |
| VI | Malignant | 97-99% | Surgery |
(Source: Mulholland & Greenfield's Surgery 7e, Table 75.5)
Bethesda III means: The cytology findings are "indeterminate" - they cannot be definitively called benign or malignant from this FNAC alone. The actual cancer risk in surgically removed Bethesda III nodules is approximately 14% (range 6-48%) - meaning about 14 in 100 such nodules, when removed, turn out to be cancerous.
What Happens Next - Management Options
This report does not mean cancer is confirmed. It means the nodule needs further evaluation. Based on current surgical guidelines (Current Surgical Therapy 14e, Mulholland & Greenfield's Surgery 7e):
1. Repeat FNAC (most common first step)
- Repeat FNAC resolves the diagnosis in more than 50% of Bethesda III cases - many come back as clearly benign on a second sample
- Typically done after 3-6 months
2. Molecular Testing (if available)
- Tests like ThyroSeq v3 or Afirma Gene Expression Classifier can analyze the nodule's genetic makeup
- These can reclassify many Bethesda III nodules as benign (avoiding unnecessary surgery) or confirm high-risk features
- ThyroSeq v3 has ~94% specificity for Bethesda III/IV nodules - a benign result can avoid surgery in up to 61% of patients
3. Diagnostic Lobectomy (surgical removal of the left thyroid lobe)
- Considered if: repeat FNAC remains indeterminate, molecular testing is unavailable, or nodule features are concerning
- Removes the nodule for definitive histopathological diagnosis
- Given the TR4 ultrasound classification + microcalcifications in a 30-year-old, the treating surgeon may lean toward surgery
4. Observation
- Reasonable only if the patient opts against surgery and molecular testing is reassuring
- Requires serial ultrasound monitoring
Key Points to Discuss with the Doctor
- This is NOT a cancer diagnosis. It is an indeterminate result that requires follow-up.
- The microcalcifications + TR4 on ultrasound are the more concerning features here and typically prompt a more proactive approach.
- At age 30, a thorough evaluation is warranted - younger patients with thyroid nodules have a slightly different risk-benefit balance for surgery.
- Ask about molecular testing availability in your area before committing to surgery - it can help avoid an operation if it returns a low-risk result.
- The treating endocrinologist or thyroid surgeon should correlate this with TSH levels, T3/T4, and thyroid antibody tests if not already done.
A recent 2026 meta-analysis (PMID 42118459) confirms that molecular testing significantly impacts surgical decision-making in indeterminate thyroid nodules and can reduce unnecessary lobectomies.
Important: This explanation is for informational purposes only. The family should consult an endocrinologist or endocrine surgeon for personalized management. Do not delay follow-up given the TR4 classification.
Age 22 years
The report states the patient is 30 years old, but you're saying she is actually 22. This changes the clinical picture somewhat - younger patients with thyroid nodules carry a modestly higher risk of malignancy compared to older adults, and management decisions shift accordingly.
Here is what changes at age 22:
How Age 22 Affects This Report
Higher Baseline Malignancy Risk
Thyroid nodules in patients under 25 years old are statistically more likely to be malignant than the same nodule in a middle-aged adult. While the overall Bethesda III malignancy risk is 5-15%, younger age is an independent risk factor that pushes toward the higher end of that range. Combined with:
- TR4 on ultrasound (moderately suspicious)
- Microcalcifications within the nodule
- Focal nucleomegaly on cytology
...the overall clinical suspicion is meaningfully higher than a straightforward Bethesda III in an older patient.
Longer Life Ahead = Lower Threshold for Definitive Diagnosis
At 22, even a small risk of undetected malignancy carries decades of potential consequence. Most thyroid surgeons and endocrinologists would counsel a lower threshold for diagnostic lobectomy in a young patient with these ultrasound features, rather than a prolonged watch-and-wait approach.
Fertility and Hormonal Considerations
- If lobectomy is performed, one lobe of the thyroid remains and most 22-year-olds maintain normal thyroid function afterward
- Full thyroidectomy (if ever needed) would require lifelong thyroxine replacement - important for future pregnancies
- These factors should be discussed explicitly with the surgeon
Recommended Action Plan for a 22-Year-Old with This Report
| Priority | Step | Reason |
|---|---|---|
| 1st | See an endocrinologist or thyroid surgeon urgently | Needs clinical + ultrasound correlation |
| 2nd | Check TSH, Free T4, Anti-TPO antibodies (if not done) | Baseline thyroid function |
| 3rd | Molecular testing (ThyroSeq v3 or Afirma) if available | Can avoid surgery if result is reassuring |
| 4th | Diagnostic left hemithyroidectomy (lobectomy) | Likely recommended given age + TR4 + microcalcifications |
Bottom Line
At age 22 with a TR4 nodule showing microcalcifications and Bethesda III cytology, most guidelines and most experienced thyroid surgeons would recommend not waiting for a repeat FNAC alone. The combination of young age, suspicious ultrasound features, and an indeterminate cytology result typically favors proceeding to diagnostic lobectomy or at minimum molecular testing to rule out malignancy definitively.
The good news: even if the nodule turns out to be malignant (most commonly papillary thyroid carcinoma in this age group), thyroid cancer in young women has an excellent prognosis with appropriate surgical treatment - survival rates exceed 98% for well-differentiated thyroid cancers caught at this stage.
Please consult an endocrinologist or endocrine/head-and-neck surgeon as soon as possible - ideally within the next 1-2 weeks given the TR4 classification.
This is a shared conversation. Sign in to Orris to start your own chat.